Cell therapy for macular degeneration--first phase I/II pluripotent stem cell-based clinical trial shows promise

Affiliations

¹ Cell Therapy Center, Xuanwu Hospital, Capital Medical University, and Key Laboratory of Neurodegeneration, Ministry of Education, Beijing, 100053, China, chenzhiguo@gmail.com.

Comment

ZhiGuo Chen et al. Sci China Life Sci. 2015 Jan.

. 2015 Jan;58(1):119-20.

doi: 10.1007/s11427-014-4791-2. Epub 2014 Dec 20.

¹ Cell Therapy Center, Xuanwu Hospital, Capital Medical University, and Key Laboratory of Neurodegeneration, Ministry of Education, Beijing, 100053, China, chenzhiguo@gmail.com.

No abstract available

Comment on

Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies.
Schwartz SD, Regillo CD, Lam BL, Eliott D, Rosenfeld PJ, Gregori NZ, Hubschman JP, Davis JL, Heilwell G, Spirn M, Maguire J, Gay R, Bateman J, Ostrick RM, Morris D, Vincent M, Anglade E, Del Priore LV, Lanza R. Schwartz SD, et al. Lancet. 2015 Feb 7;385(9967):509-16. doi: 10.1016/S0140-6736(14)61376-3. Epub 2014 Oct 15. Lancet. 2015. PMID: 25458728 Clinical Trial.